Wyden Amdt. No. 5336
Senate Roll Call #103 • 119th Congress
Amendment Rejected
Roll Call #103
What This Amendment Does
To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer.
What This Vote Means
This amendment was REJECTED and will not be included in the bill.
Required to pass: 1/2 majority (51 votes, or 50 + VP)
April 23, 2026
119th Congress, Session 2
48
Yea
48.0%
50
Nay
50.0%
0
Present
0.0%
2
Not Voting
2.0%
Vote by Party
Democrats (45)
Yea: 44
Nay: 0
Not Voting: 1
Republicans (53)
Yea: 2
Nay: 50
Not Voting: 1
Independents (2)
Yea: 2
Nay: 0
Yea (48)
Republican
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Republican
Independent
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
NJ
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Democrat
Independent
Democrat
Democrat
Democrat
Democrat
Nay (50)
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
NC
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Alan Armstrong
OK
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
Republican
TX
Republican
Republican
UT
Republican
Republican
Republican
Republican
Republican
Republican
Not Voting (2)
Republican
Democrat
Data source: senate-xml-feed•Processed: 7/6/2026•Confidence: high